Saralasin

Star0

DB06763ExperimentalSmall molecule

Saralasin: Overview.

Mechanism: Pharmacologically active on Type-1 angiotensin II receptor
Curator reviewed
Formula / weight: C₄₂H₆₅N₁₃O₁₀ · 912.063 g/mol (avg)
Code names: P-113

Resolves to

Compound

UNIIH2AFV2HE66CAS34273-10-4ChEMBLCHEMBL938ChEBI135894

Clinical / RWD

RxNorm9556

Structure

InChIKeyPFGWGEPQIUAZME-NXSMLHPHSA-NSMILES

[H]N([H])C(=NCCC[C@H](N([H])C(=O)CN([H])C)C(=O)N([H])[C@@H](C(C)C)C(=O)N([H])[C@@H](CC1=CC=C(O)C=C1)C(=O)N([H])[C@@H](C(C)C)C(=O)N([H])[C@@H](CC1=CN=CN1[H])C(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](C)C(O)=O)N([H])[H]

Targets

P30556AGTR1P50052AGTR2

What you can answer from here — as of September 21, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

680Drug interactionsStructured to mechanism, not free text

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Saralasin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account